In brief: Cytopia; LCT; Rockeby
Thursday, 10 March, 2005
Cytopia (ASX:CYT) today filed an Investigational New Drug Application with the US Food and Drug Administration, seeking approval to test its cancer drug candidate CYT997 in the clinic.
Rockeby biomed (ASX:RBY) has announced the resignation of Dr John Warmington as the company's director of research and development. Warmington assume a consultancy role with the company as chief scientist. Dr David Capes will take up the position of vice president of research and development.
Xenotransplantation company Living Cell Technologies (ASX: LCT) has appointed Paris Brooke as general manager. Brooke was formerly policy and communication manager at AusBiotech.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
